Purple Biotech Q2 EPS $(0.09) Beats $(0.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
Purple Biotech (NASDAQ:PPBT) reported a Q2 EPS of $(0.09), beating the analyst consensus estimate of $(0.12) by 25%. This represents a 64% improvement over the $(0.25) per share loss from the same period last year.
August 16, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Purple Biotech reported a Q2 EPS of $(0.09), beating the analyst consensus estimate of $(0.12) by 25%. This is a significant improvement over the $(0.25) per share loss from the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact Purple Biotech's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100